| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00007890-199703150-00009 |
| P698 | PubMed publication ID | 9075835 |
| P2093 | author name string | Goldstein DJ | |
| Cohen D | |||
| Weinberg AD | |||
| Zuech N | |||
| Drusin R | |||
| Sehgal V | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | kidney disease | Q1054718 |
| P304 | page(s) | 664-668 | |
| P577 | publication date | 1997-03-01 | |
| P1433 | published in | Transplantation | Q15730500 |
| P1476 | title | Cyclosporine-associated end-stage nephropathy after cardiac transplantation: incidence and progression | |
| P478 | volume | 63 |
| Q73012938 | A new model of chronic cyclosporine nephrotoxicity for comparative morphologic and histologic studies |
| Q35835015 | A randomized cross-over comparison of short-term exposure of once-daily extended release tacrolimus and twice-daily tacrolimus on renal function in healthy volunteers |
| Q81453722 | Advantages of peritoneal dialysis in comparison to hemodialysis, in cardiac allograft recipients with end stage renal disease |
| Q33693223 | An animal model of chronic cyclosporine nephrotoxicity |
| Q46024446 | Analysis of survivors more than 10 years after heart transplantation in the cyclosporine era: Stanford experience. |
| Q46843863 | Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients |
| Q44498148 | Benefit of theophylline administration in tacrolimus-induced nephrotoxicity in rats |
| Q35772548 | Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients |
| Q57893157 | C2 monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses |
| Q44524563 | Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years |
| Q44311694 | Chronic renal failure and end-stage renal disease are associated with a high rate of mortality after heart transplantation |
| Q38240994 | Chronic renal insufficiency in heart transplant recipients: risk factors and management options |
| Q35106109 | Comparison of survival of patients with heart and lung transplants on peritoneal dialysis and hemodialysis |
| Q73538927 | Creatinine-based estimation of rate of long term renal function loss in lung transplant recipients. Which method is preferable? |
| Q35711226 | Cyclosporine in thoracic organ transplantation |
| Q51788749 | Cyclosporine withdrawal improves renal function in heart transplant patients on reduced-dose cyclosporine therapy. |
| Q44118346 | Decline in renal function following thoracic organ transplantation in children |
| Q38232442 | Deferasirox nephrotoxicity-the knowns and unknowns |
| Q43551965 | Early detection of heart transplant patients with increased risk of ciclosporin nephrotoxicity |
| Q28343894 | Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain |
| Q51189916 | Empiric switch from calcineurin inhibitor to sirolimus-based immunosuppression in pediatric heart transplantation recipients. |
| Q34053103 | Endothelin-receptor antagonists: current and future perspectives |
| Q45248065 | Erythrocyte sodium lithium countertransport in renal transplant recipients with mycophenolate mofetil and low-dose cyclosporine |
| Q40522553 | Experience with cyclosporine |
| Q35710914 | Experience with cyclosporine in the Canary Islands |
| Q43836681 | First experience with de novo calcineurin-inhibitor-free immunosuppression following cardiac transplantation |
| Q39711763 | Former smoking is a risk factor for chronic kidney disease after lung transplantation |
| Q36836432 | Heart Retransplant Recipients Have Better Survival With Concurrent Kidney Transplant Than With Heart Retransplant Alone |
| Q33535928 | Heart allograft vascular disease: an obliterative vascular disease in transplanted hearts |
| Q46475765 | Heart transplant recipient clinical profile improvement following mycophenolate mofetil late incorporation into the treatment schedule |
| Q44437931 | How should sirolimus be used in clinical practice? |
| Q33804467 | Immunosuppressant-induced nephropathy: pathophysiology, incidence and management |
| Q36978156 | Immunosuppressive therapy in older cardiac transplant patients |
| Q44491120 | Impact of cardiac transplantation on kidney function: a single- center experience |
| Q44412745 | Impact of cyclosporine 2‐h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti‐thymocyte globulin induction |
| Q36498564 | Impact of the early reduction of cyclosporine on renal function in heart transplant patients: a French randomised controlled trial |
| Q95380157 | Improvement in chronic renal failure after mycophenolate mofetil introduction and cyclosporine dose reduction: four-year results from a cohort of heart transplant recipients |
| Q89718109 | Invasive haemodynamics in de novo everolimus vs. calcineurin inhibitor heart transplant recipients |
| Q90480119 | Kidney Dysfunction After Vascularized Composite Allotransplantation |
| Q36422125 | Kidney disease after heart and lung transplantation |
| Q46958937 | Long-term renal function in heart transplant children on cyclosporine treatment |
| Q80888688 | Management of the Patient After Heart Transplant |
| Q73027657 | Mycophenolate mofetil overlap in liver transplant recipients with chronic cyclosporine nephrotoxicity |
| Q73314783 | Mycophenolate mofetil-based immunosuppressive therapy: induction, maintenance, and conversion protocols in renal transplantation |
| Q33920665 | Neoral use in the cardiac transplant recipient |
| Q73453363 | Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future |
| Q82888310 | Our experience in cardiac transplantation in Baskent University |
| Q44779317 | Outcomes after heart transplantation in patients with and without pretransplant renal dysfunction |
| Q44311127 | Outcomes following de novo CNI-free immunosuppression after heart transplantation: a single-center experience |
| Q44311785 | Pediatric cardiac transplant: results using a steroid-free maintenance regimen |
| Q44976495 | Pharmacokinetics of sirolimus in heart transplant recipients with chronic renal impairment |
| Q44090351 | Pre-operative renal function predicts development of chronic renal insufficiency after orthotopic heart transplantation |
| Q43254691 | Predictors of kidney dysfunction in heart transplant recipients |
| Q51532710 | Preemptive use of Mammalian target of rapamycin inhibitors in living donor transplantation. |
| Q54989531 | Preliminary experience with mycophenolate mofetil for preservation of renal function in cardiac transplant patients with documented cyclosporine nephrotoxicity |
| Q84183405 | Prognostic value of glomerular filtration rate 1 year after heart transplantation |
| Q36155845 | Progressive chronic kidney disease after pediatric lung transplantation |
| Q46246123 | Randomized prospective study of the evolution of renal function depending on the anticalcineurin used |
| Q34547749 | Reducing adverse effects of immunosuppressive agents in kidney transplant recipients |
| Q36759257 | Renal and liver transplantation for toxin-induced organ failure |
| Q35072102 | Renal complications following heart transplantation in children: a single-center study |
| Q44577678 | Renal dysfunction after orthotopic heart transplantation: incidence, natural history, and risk factors |
| Q44491123 | Renal function and safety of heart transplant recipients switched to mycophenolate mofetil and low-dose cyclosporine. |
| Q73316092 | Renal function one year after switching from Sandimmun to Neoral |
| Q79774460 | Renal insufficiency and end-stage renal disease in the heart transplant population |
| Q44136534 | Reversal of chronic cyclosporine nephrotoxicity after heart transplantation-potential role of mycophenolate mofetil |
| Q45058201 | Sirolimus and mycophenolate mofetil as calcineurin inhibitor-free immunosuppression in a cardiac transplant patient with chronic renal failure |
| Q46468611 | Sirolimus improves renal function in cardiac transplantation |
| Q33376348 | Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results. |
| Q74685542 | Survival of heart transplant recipients with cyclosporine-induced renal insufficiency |
| Q73544667 | Systemic hypertension and renal function in long-term liver transplant recipients on cyclosporine |
| Q34790359 | The burden of chronic kidney disease in long-term liver transplant recipients. |
| Q36577612 | The challenge of renal function in heart transplant children |
| Q57945194 | The incidence of end-stage renal failure in 17 years of heart transplantation: a single center experience |
| Q54989546 | The natural history of renal function following orthotopic heart transplant |
| Q35175413 | Thymoglobulin induction in heart transplantation: patient selection and implications for maintenance immunosuppression. |
| Q43620682 | Urinary retinol binding protein is a good marker of progressive cyclosporine nephrotoxicity after heart transplant. |
| Q35711255 | Use of cyclosporine in thoracic transplantation |
| Q45029202 | Zinc chloride-mediated reduction of apoptosis as an adjunct immunosuppressive modality in cardiac transplantation |
Search more.